基于人肺表面活性物质生理代谢途径与功能开发安全有效的新型合成黏膜佐剂SF-10
本文综述了基于牛肺表面活性物质(PS)代谢途径与快速代谢更新特性开发黏膜佐剂SF-10的工作。SF-10与流感裂解疫苗(HAv)联用可增强抗原提呈细胞摄取,在小鼠和食蟹猴鼻内滴注可诱导全身和黏膜HAv特异性免疫,并探索了口服给药途径。
要点
- SF-10由三种PS脂质与表面活性蛋白-C复合物优化而来,旨在提高安全性、效力与生产便利性。
- HAv-SF-10在体外和体内均增强HAv被抗原提呈细胞摄取。
- 小鼠和食蟹猴鼻内滴注HAv-SF-10可诱导全身和黏膜HAv特异性免疫。
核心结论
- 成功开发了基于PS的合成黏膜佐剂SF-10,与流感裂解疫苗联用可诱导全身和黏膜免疫。
研究设计与样本
- 综述类文章,总结作者团队关于PS基鼻用和口服黏膜佐剂用于流感疫苗的开发工作。
主要发现
- PS佐剂性的必需组分为三种PS脂质与表面活性蛋白-C的复合物,可增强疫苗抗原递送并激活抗原提呈细胞。
- HAv-SF-10在体外和体内增强HAv掺入抗原提呈细胞。
- 小鼠和食蟹猴鼻内滴注HAv-SF-10可诱导全身和黏膜HAv特异性免疫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A safe and effective mucosal adjuvant is required for vaccination against influenza A virus (IAV) infection. Previously, we described that intranasally administration of surfacten®, a medicine derived from bovine pulmonary surfactant (PS), with IAV vaccine can induce IAV-specific IgA in the respiratory tract mucosa and IgG in serum. PS is secreted by alveolar type II cells and Clara cells and serves to reduce lung surface tension. PS finished its rules is incorporated by antigen presenting cells (APCs), such as alveolar macrophages and dendritic cells, and alveolar type II cells and rapidly metabolized. We focused on the metabolic pathways and rapid metabolic turnover of PS and developed a PS-based mucosal adjuvant. First, we determined the essential components of PS adjuvanticity and found that the complex of three PS lipids and surfactant protein-C can enhance to deliver the vaccine antigen and activate APCs. Later, we improved the safety, efficacy and ease of manufacture and finally succeeded in developing SF-10. The use of SF-10 with influenza split vaccine (HAv) (HAv-SF-10) enhances HAv incorporation into APCs both in vitro and in vivo, and intranasal instillation of HAv-SF-10 induced systemic and mucosal HAv-specific immunities in not only mice but also cynomolgus monkeys. The report that PS has physiological effects on the gastrointestinal mucosa prompted us develop a new SF-10-based vaccine that can be administered orally. In this review, We summarize our work on the development of clinically effective PS-based nasal and oral mucosal adjuvants for influenza vaccine.
引用
- Kimoto T. Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant. Vaccine. 2021. PMID: 34887132. doi:10.1016/j.vaccine.2021.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。